Month: March 2025

Mar 03 2025

Uncategorized

Teva targets schizophrenia to build on innovative medicines growth – PharmaVoice

by Clinical Editor

No Comments

Teva targets schizophrenia to build on innovative medicines growth  PharmaVoice

Mar 02 2025

Uncategorized

Understanding the suicide risk in schizophrenia

by Clinical Editor

No Comments

Suicide rates for schizophrenia are among the highest of any mental illness, but suicide prevention strategies can make a difference. Read more.

Mar 02 2025

Uncategorized

Subtle differences identified in brains of people with schizophrenia

by Clinical Editor

No Comments

The subtleties involved here reflect the fact that the brain’s dizzying complexity means it’s rarely possible to draw simple conclusions. Even in this case, where a basic interpretation might be...

Mar 01 2025

Uncategorized

FDA Makes Access to Clozapine Easier for Patients With Schizophrenia

by Clinical Editor

No Comments

FRIDAY, Feb. 28, 2025 (HealthDay News) — The U.S. Food and Drug Administration has removed one hurdle faced by patients with schizophrenia when filling prescriptions for the antipsychotic medication …

Mar 01 2025

Uncategorized

F.D.A. Expands Access to Clozapine, a Key Treatment for Schizophrenia

by Clinical Editor

No Comments

Federal regulators will no longer require patients to provide blood tests before receiving the drug from pharmacies.